Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Liver Diseases × tislelizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3 Carcinoma, Hepatocellular 3 Rectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Liver Diseases 1 Hypersensitivity 1 Biliary Tract Neoplasms 1 Advanced Colorectal Carcinoma 1

Interventions

Blood Specimen Collection 2 toripalimab 1 tislelizumab 1 sintilimab 1 pembrolizumab 1 lenvatinib 1 gadolinium ethoxybenzyl DTPA 1 camrelizumab 1 User-Centered Design 1 Nivolumab 1 Neuropsychological Tests 1 Lead 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡